Asked by: Lord Taylor of Warwick (Non-affiliated - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what assessment they have made of the use of AI-enabled assistive technologies, including wearable devices, in supporting people living with dementia; and what steps they are taking to ensure those technologies are safe, effective and accessible while maintaining standards of data protection and patient care.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
The Government recognises the potential of artificial intelligence (AI) enabled assistive technologies, including wearable devices, to support people living with dementia by promoting independence, safety, and quality of life, and by helping carers and care professionals provide more personalised and responsive support.
To help assess the use of technologies in adult social care, the Government has funded the testing and evaluation of technologies, including AI-enabled technologies, through the Adult Social Care Technology Fund. Emerging evidence indicates positive outcomes for people in receipt of care, care professionals, and the wider health and social care system. People using technology experienced greater independence, safety, wellbeing, and quality of life. We will publish the findings from these projects.
We are in the process of developing trusted, accessible guidance and setting new standards for care technologies, including evidence standards which will help people identify which tech might be most useful for them. This will help people living with dementia, their carers', and care providers know which technologies are fit for purpose, secure, and compatible with the wider health and social care systems in the future, supporting them to invest in technology for the long term.
Asked by: Tom Morrison (Liberal Democrat - Cheadle)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to support those suffering from primary progressive aphasia.
Answered by Stephen Kinnock - Minister of State (Department of Health and Social Care)
The provision of dementia health care services is the responsibility of local integrated care boards (ICBs) and may include speech and language therapy. We expect ICBs to commission services based on local population needs, taking account of National Institute for Health and Care Excellence guidelines.
The Government is committed to improving care for everyone with dementia, including those with Primary Progressive Aphasia, which is why we have funded the work of the Dementia 100: Assessment Tool Pathway programme, which brings together multiple resources into a single, consolidated tool. This will help simplify best practice for busy system leaders and help create communities and services where the best possible care and support is available to those with dementia.
A number of experts, including those with expertise in speech and language therapy and dementia care, provided independent, desktop analysis of the tool, and this invaluable feedback was integrated into the tool. The D100: Pathway Assessment Tool can be found at the following link:
Asked by: Tom Morrison (Liberal Democrat - Cheadle)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what support is available for those suffering from primary progressive aphasia.
Answered by Stephen Kinnock - Minister of State (Department of Health and Social Care)
The provision of dementia health care services is the responsibility of local integrated care boards (ICBs) and may include speech and language therapy. We expect ICBs to commission services based on local population needs, taking account of National Institute for Health and Care Excellence guidelines.
The Government is committed to improving care for everyone with dementia, including those with Primary Progressive Aphasia, which is why we have funded the work of the Dementia 100: Assessment Tool Pathway programme, which brings together multiple resources into a single, consolidated tool. This will help simplify best practice for busy system leaders and help create communities and services where the best possible care and support is available to those with dementia.
A number of experts, including those with expertise in speech and language therapy and dementia care, provided independent, desktop analysis of the tool, and this invaluable feedback was integrated into the tool. The D100: Pathway Assessment Tool can be found at the following link:
Asked by: Mike Reader (Labour - Northampton South)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether he plans to develop a modern service framework for neurological conditions; and what steps he is taking to attract, train and retain specialist healthcare professionals for Parkinson’s.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
The first wave of modern service frameworks will include cardiovascular disease, sepsis, mental health, palliative care and end-of-life care, and dementia and frailty. The Government will consider other conditions with significant health and economic impacts for future waves of modern service frameworks in due course.
The Government is committed to publishing a 10 Year Workforce Plan to set out action to create a workforce ready to deliver the transformed service set out in the 10-Year Health Plan. The 10 Year Workforce Plan will ensure the National Health Service has the right people in the right places, with the right skills to care for patients, when they need it.
NHS staff told us through the 10-Year Health Plan engagement that they are crying out for change. This workforce plan will set out how we will deliver that change by making sure that staff are better treated, have better training, more fulfilling roles, and hope for the future.
We have set up a United Kingdom-wide Neuro Forum, facilitating formal, twice-yearly meetings across the Department, NHS England, the devolved administrations, and health services and Neurological Alliances of all four nations. The new forum brings key stakeholders together to share learnings across the system and discuss challenges, best practice examples, and potential solutions for improving the care of people with neurological conditions. The forum has identified areas for initial focus, including workforce, which featured as a key item on the agenda at the third meeting of the forum on 18 March.
Asked by: Victoria Collins (Liberal Democrat - Harpenden and Berkhamsted)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what recent steps his Department has taken to increase the number and capacity of dementia trials.
Answered by Stephen Kinnock - Minister of State (Department of Health and Social Care)
Government responsibility for delivering dementia research is shared between the Department for Health and Social Care, with research delivered by the National Institute for Health and Care Research (NIHR), and the Department for Science, Innovation and Technology, with research delivered via UK Research and Innovation (UKRI).
The Department for Health and Social Care is committed to ensuring that all patients, including those with dementia, have access to cutting-edge clinical trials and innovative, lifesaving treatments. Government funding is already enabling the dementia clinical trials landscape to become more efficient and accessible.
The Dame Barbara Windsor Dementia Goals programme, with up to £150 million expected to be allocated to, or aligned with it, aims to speed up the development of new treatments for dementia and neurodegenerative conditions by accelerating innovations in biomarkers, clinical trials, and implementation.
Closely aligned to the programme, the NIHR has invested up to £50 million into the UK Demetia Trials Network (UKDTN). UKDTN aims to expand the United Kingdom’s early phase clinical trial capabilities in dementia by addressing industry challenges around trial recruitment and fragmented research infrastructure. The UKDTN will establish a coordinated network of over 20 trial sites, with a real-time database to enable efficient identification of trial sites for industry collaboration. The network will also build a skilled workforce of dementia trial specialists, including early-career researchers, and embedded research nurses to support trial set-up and delivery.
In addition, the Medical Research Council’s £20 million investment into a Dementia Trials Accelerator aims to embed more innovation in how clinical trials are designed and delivered in order to increase the speed and quality, while driving down the cost of large-scale trials.
In partnership with Alzheimer’s Society, Alzheimer’s Research UK, and Alzheimer Scotland, the NIHR also delivers Join Dementia Research, an online platform which enables the involvement of people with and without a dementia diagnosis, as well as carers, to take part in a range of important research, including studies evaluating potential treatments for dementia. As of March 2026, over 110,000 participants have joined dementia research through the service, with 112 studies currently open.
Asked by: Victoria Collins (Liberal Democrat - Harpenden and Berkhamsted)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential to scale up investment in dementia clinical trials, including through the Dementia Goals Programme.
Answered by Stephen Kinnock - Minister of State (Department of Health and Social Care)
Government responsibility for delivering dementia research is shared between the Department for Health and Social Care, with research delivered by the National Institute for Health and Care Research (NIHR), and the Department for Science, Innovation and Technology, with research delivered via UK Research and Innovation (UKRI).
The Department for Health and Social Care is committed to ensuring that all patients, including those with dementia, have access to cutting-edge clinical trials and innovative, lifesaving treatments. Government funding is already enabling the dementia clinical trials landscape to become more efficient and accessible.
The Dame Barbara Windsor Dementia Goals programme, with up to £150 million expected to be allocated to, or aligned with it, aims to speed up the development of new treatments for dementia and neurodegenerative conditions by accelerating innovations in biomarkers, clinical trials, and implementation.
Closely aligned to the programme, the NIHR has invested up to £50 million into the UK Demetia Trials Network (UKDTN). UKDTN aims to expand the United Kingdom’s early phase clinical trial capabilities in dementia by addressing industry challenges around trial recruitment and fragmented research infrastructure. The UKDTN will establish a coordinated network of over 20 trial sites, with a real-time database to enable efficient identification of trial sites for industry collaboration. The network will also build a skilled workforce of dementia trial specialists, including early-career researchers, and embedded research nurses to support trial set-up and delivery.
In addition, the Medical Research Council’s £20 million investment into a Dementia Trials Accelerator aims to embed more innovation in how clinical trials are designed and delivered in order to increase the speed and quality, while driving down the cost of large-scale trials.
In partnership with Alzheimer’s Society, Alzheimer’s Research UK, and Alzheimer Scotland, the NIHR also delivers Join Dementia Research, an online platform which enables the involvement of people with and without a dementia diagnosis, as well as carers, to take part in a range of important research, including studies evaluating potential treatments for dementia. As of March 2026, over 110,000 participants have joined dementia research through the service, with 112 studies currently open.
Asked by: James McMurdock (Independent - South Basildon and East Thurrock)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential impact of an ageing prison population on demand for healthcare services within prisons.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
As a signatory to the National Partnership Agreement for Health and Social Care for people in contact with the criminal justice system, the Department of Health and Social Care is committed to working with the Ministry of Justice, His Majesty’s Prison and Probation Service, NHS England and the UK Health Security Agency to ensure safe, legal, decent and effective care that improves health outcomes and reduces health inequalities is provided for all prisoners, including those who are elderly.
NHS England is responsible for providing a full range of healthcare services to meet the needs of the prison population. Every prison will have a health needs assessment undertaken on a regular basis which is then used to locally determine the health needs and requirements of that prison’s population. This includes supporting elderly prisoners on their palliative care, end of life care and other health needs such as dementia care. Local authorities also have a duty to support elderly prisoners with their social care needs.
The Dying Well in Custody Charter and supporting self-assessment framework describes a set of national standards for local adoption and provides a tool for a local multi-disciplinary approach to providing agreed standards of palliative and end of life care to people in prison. The Charter is available at the following link:
https://www.england.nhs.uk/long-read/dying-well-in-custody-charter/
Asked by: Rachael Maskell (Labour (Co-op) - York Central)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether his Department plans to issue guidance to Integrated Care Boards on commissioning speech and language therapy services for people with primary progressive aphasia.
Answered by Stephen Kinnock - Minister of State (Department of Health and Social Care)
The Government is committed to improving care for everyone with dementia, which is why we have funded the work of Dementia 100: Assessment Tool Pathway programme. This brings together multiple resources into a single, consolidated tool and will help simplify best practice. A number of experts, including those with expertise in speech and language therapy and dementia care, provided independent, desktop analysis of the tool and this invaluable feedback was integrated into the tool. The D100: Pathway Assessment Tool can be found at the following link:
We will also deliver the first ever Modern Service framework for Frailty and Dementia to deliver rapid and significant improvements in quality of care and productivity. This will be informed by phase one of the independent commission into adult social care, which is expected this year. The Frailty and Dementia Modern Service Framework will seek to reduce unwarranted variation and narrow inequality for those living with dementia and will set national standards for dementia care and redirect National Health Service priorities to provide the best possible care and support.
We are committed to publishing an interim product in September this year to feed into NHS and local government planning cycles, and will aim to publish the full modern service framework by the end of this calendar year as recommended by Baroness Casey.
Asked by: Rachael Maskell (Labour (Co-op) - York Central)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to ensure access to speech and language therapy for people with primary progressive aphasia.
Answered by Stephen Kinnock - Minister of State (Department of Health and Social Care)
The provision of dementia health care services is the responsibility of local integrated care boards (ICBs) and may include speech and language therapy. We expect ICBs to commission services based on local population needs, taking account of National Institute for Health and Care Excellence guidelines.
Patients can be referred to a speech and language therapist at any time after a diagnosis. The therapist will assess speech, language, and communication difficulties and how they are affecting the patient or making everyday life difficult. They can also help with eating, drinking, and swallowing difficulties.
Asked by: Danny Chambers (Liberal Democrat - Winchester)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether he plans to take steps to ensure that AI-based mental health tools do not replace access to human-delivered psychological support where this is clinically appropriate.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The Government is clear that artificial intelligence (AI) based tools must not replace access to human‑delivered psychological support where this is clinically appropriate.
Digital and AI tools can be used to support mental health services and those in need of those services, for example by helping with administrative tasks, triage, or appointment management, and these benefits can enable clinicians to spend more time delivering direct care. However, decisions about treatment and care must always be clinically led and based on individual patient need.
Publicly available AI applications that are not deployed by the National Health Service, such as ChatGPT or Google Gemini, are not regulated as medical technologies and may offer incorrect or harmful information. People experiencing mental health difficulties are strongly encouraged to seek support from qualified professionals through NHS services or trusted charities.
Spending across mental health services, both specialised commissioning and ICB combined, and including learning disability, autism, and dementia, is planned to increase to £20.616 billion in 2025/26, compared to £18.988 billion in 2024/25. Specific funding has also been allocated to expand mental health support in schools to 100% of institutions by 2029/30.